Tumor Neoantigen vaccine-induced tumor-specific T-cell therapy (NeoCura Bio Medical Technology)

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameTumor Neoantigen vaccine-induced tumor-specific T-cell therapy (NeoCura Bio Medical Technology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNeoCura Bio Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeoCura Bio Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A